Dadras Omid, Mehraeen Esmaeil, Karimi Amirali, Tantuoyir Marcarious M, Afzalian Arian, Nazarian Newsha, Mojdeganlou Hengameh, Mirzapour Pegah, Shamsabadi Ahmadreza, Dashti Mohsen, Ghasemzadeh Afsaneh, Vahedi Farzin, Shobeiri Parnian, Pashaei Zahra, SeyedAlinaghi SeyedAhmad
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. E-mail:
School of Public Health, Walailak University, Nakhon Si Thammarat, Thailand. E-mail:
Arch Acad Emerg Med. 2022 Jul 7;10(1):e54. doi: 10.22037/aaem.v10i1.1585. eCollection 2022.
Knowledge of the safety of vaccines is crucial, both to prevent and cure them and to decrease the public hesitation in receiving vaccines. Therefore, this study aimed to systematically review the adverse events reported for inactivated vaccines and Novavax.
In this systematic review, the databases of PubMed, Scopus, Cochrane, and Web of Science were searched on September 15, 2021. Then we identified the eligible studies using a two-step title/abstract and full-text screening process. Data on the subjects, studies, and types of adverse events were extracted and entered in a word table, including serious, mild, local, and systemic adverse events as well as the timing of side effects' appearance.
Adverse effects of inactivated coronavirus vaccines side effects were reported from phases 1, 2, and 3 of the vaccine trials. The most common local side effects included injection site pain and swelling, redness, and pruritus. Meanwhile, fatigue, headache, muscle pain, fever, and gastrointestinal symptoms including abdominal pain and diarrhea were among the most common systemic adverse effects.
This systematic review indicates that inactivated COVID-19 vaccines, including Sinovac, Sinopharm, and Bharat Biotech, as well as the protein subunit vaccines (Novavax) can be considered as safe choices due to having milder side effects and fewer severe life-threatening adverse events.
疫苗安全性知识至关重要，对于预防和治疗疾病以及减少公众对接种疫苗的犹豫情绪都很关键。因此，本研究旨在系统回顾已报告的灭活疫苗和诺瓦瓦克斯疫苗的不良事件。
在这项系统评价中，于2021年9月15日检索了PubMed、Scopus、Cochrane和科学网数据库。然后我们通过两步标题/摘要和全文筛选过程确定符合条件的研究。提取关于受试者、研究和不良事件类型的数据，并录入一个word表格，包括严重、轻度、局部和全身不良事件以及副作用出现的时间。
在疫苗试验的1、2、3期均报告了灭活冠状病毒疫苗的副作用。最常见的局部副作用包括注射部位疼痛、肿胀、发红和瘙痒。同时，疲劳、头痛、肌肉疼痛、发热以及包括腹痛和腹泻在内的胃肠道症状是最常见的全身不良反应。
本系统评价表明，包括科兴、国药和巴拉特生物技术公司生产的灭活新冠疫苗以及蛋白亚单位疫苗（诺瓦瓦克斯疫苗），由于副作用较轻且严重危及生命的不良事件较少，可被视为安全选择。
